Palatin Technologies Incorporated

Wei Yang

Shubh D Sharma

Yi-Qun Shi

Hui-Zhi Cai

Margarita Bastos

Annette M Shadiack

Xin Chen

Ramesh Rajpurohit

John H Dodd

Yiqun Shi

Shubh D Sharama

Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.

Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy

Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R, R, R, R, R, R, R, R, Rand Rare as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.

Melanocortin receptor-specific peptide with C-terminal naphthylalanine

Melanocortin receptor-specific cyclic peptides of the formula where R, R, R, Rand Rare as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific peptides

Melanocortin receptor-specific cyclic peptides of the formula where R, R, R, R, R, R, R, R, R, Rand z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific linear peptides of the formulaZ-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Y&#x2003;&#x2003;(VI)

Melanocortin-1 receptor-specific linear peptides

Melanocortin receptor-specific cyclic hexapeptides of the formula where R, R, R, R, R, R, R, Rand Rare as defined in the claims, compositions and formulations including the hexapeptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

Melanocortin-1 receptor-specific cyclic hexapeptides

Melanocortin receptor-specific linear peptides of the formula where R, R, R, R, R, R, R, R, Rand Rare as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

Melanocortin receptor-specific cyclic heptapeptides of the formulaZ-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Y&#x2003;&#x2003;(II)or a pharmaceutically acceptable salt thereof, where Z, Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaaand Y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific heptapeptides

Melanocortin receptor-specific cyclic peptides of the formula where R, R, R, R, R, R, R, Rand Rare as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

Melanocortin-1 receptor-specific cyclic peptides

Lactam-bridged melanocortin receptor-specific cyclic peptides of the formula where R, R, R, R, R, R, R, Rand Rare as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including obesity, modulation of feeding behavior, related metabolic syndrome, sexual dysfunction, male erectile dysfunction and female sexual dysfunction.

Lactam-bridged melanocortin receptor-specific peptides

Methods for use of a melanocortin receptor agonist cyclic peptide of the formula where R, x and y are as defined in the specification, and compositions and formulations including the peptide of the foregoing formula, for preventing, ameliorating or treating female sexual dysfunction.

Melanocortin receptor-specific peptides for treatment of female sexual dysfunction

Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R', Q, Y, W, Z, J, x and n are as defined in the specification, and a cyclic linkage including one or two amide bonds, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.

Growing community of inventors

Edison, NJ, United States of America

Wei Yang